en · de · es · fr · pt
aod-9604-notes.peptides5388.com › Wiki › Measurement And Storage Practices — Reference Sheet

Measurement And Storage Practices — Reference Sheet

By Editorial Desk · published 2025-09-18 · last reviewed 2025-10-24 · Wiki

lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-10-24. Numbers and descriptions here follow the published literature rather than marketing material.

Measurement and Storage Practices

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form
SolubilitySoluble in waterAlso soluble in aqueous buffers
Storage temperature-20°C or belowProtect from light and moisture
Analytical methodRP-HPLCPurity and identity assessment
Mass confirmationMass spectrometryVerifies molecular mass

Background and Molecular Identity

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Related pages on this site

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Regulation and Detection Context

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Background and Development History

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Further detail

Wenger's arrival at Arsenal was greeted with perplexity by some of the club's players, supporters and the local media. Although he was touted as a future technical director of The Football Association (FA), he was relatively unknown in English football. Glenn Moore's report in The Independent, dated 24 September 1996, highlighted the mood: "It is a measure of the insularity of the English game that when Arsène Wenger's name emerged as Arsenal's favoured candidate for their vacant manager's job many supporters were asking: 'Arsène who?'" Unlike his predecessors, Wenger was given control over transfers, contracts and training sessions, and the Arsenal board chose not to meddle in team affairs. One of his first acts as manager was to assure the experienced players they had a future at the club, but he noted the squad was "a bit tight," and needed competition for places. Wenger adopted a hands-on approach to training sessions which energised the squad, and made steps to change the drinking culture that afflicted Arsenal. Although he initially allowed players to have a pint of beer, they were forbidden to drink on days off and in the players' lounge. He later banned his players from casually drinking together. Wenger also promoted pasta as the pre-match dish, encouraged boiled chicken instead of red meat and discouraged junk food. Players received optional vitamin injections and Creatine, which reduced fatigue and improved their stamina.

embassy vehicles and staff were no longer immune from penalties for traffic violations. American diplomats were asked to show work contracts for all domestic help (cooks, gardeners, drivers and security staff) employed within their households. Indian authorities also conducted an investigation into the American Embassy School. Nancy J. Powell, the U.S. ambassador to India, resigned following the incident, which was widely seen by India "as fallout from the imbroglio." Some commentators suggested that the incident and response could lead to wider damage in U.S.–India relations. Former Finance Minister Yashwant Sinha called for the arrest of same-sex companions of US diplomats, citing the Supreme Court of India's upholding of Section 377 of the Indian Penal Code whereby homosexuality is illegal in India. Former State Department legal advisor John Bellinger questioned whether the decision to arrest and detain Khobragade was "wise policy ... even if technically permissible" under the Vienna Convention on Consular Relations, while Robert D. Blackwill, the former U.S. ambassador to India from 2001 to 2003, said the incident was "stupid." Nevertheless, within a year of the incident, U.S.-India relations were warming again, as U.S. President Obama visited India in January 2015.

The toxicological cause of the disease has been attributed to the neurotoxin ODAP which acts as a structural analogue of the neurotransmitter glutamate. Lathyrism can also be caused by deliberate food adulteration.

While advertising of tobacco products is banned in most countries, television and radio e-cigarette advertising in several countries may be indirectly encouraging traditional cigarette use. E-cigarette advertisements are also in magazines, newspapers, online, and in retail stores. Between 2010 and 2014, e-cigarettes were second only to cigarettes as the top advertised product in magazines. As cigarette companies have acquired the largest e-cigarette brands, they currently benefit from a dual market of smokers and e-cigarette users while simultaneously presenting themselves as agents of harm reduction. This raises concerns about the appropriateness of endorsing a product that directly profits the tobacco industry. There is no evidence that the cigarette brands are selling e-cigarettes as part of a plan to phase out traditional cigarettes, despite some stating to want to cooperate in "harm reduction". E-cigarette advertising for using e-cigarettes as a quitting tool have been seen in the US, UK, and China, which have not been supported by regulatory bodies. In the US, six large e-cigarette businesses spent $59.3 million on promoting e-cigarettes in 2013. In the US and Canada, over $2 million is spent yearly on promoting e-cigarettes online. E-cigarette websites often made unscientific health statements in 2012. The ease to get past the age verification system at e-cigarette company websites allows underage individuals to access and be exposed to marketing.

Sources: en.wikipedia.org

Supporting material

=== Other uses === Ethyl carbamate was primarily an intermediate in the preparation of amino resins, that were in turn used as crosslinking agents for permanent-press textile treatments to create "wash-and-wear" fabrics. Other uses included as solvent or intermediates in the manufacture of pesticides, cosmetics and pharmaceuticals.

The situation has also reignited a debate over gain-of-function research, although the intense political rhetoric surrounding the issue has threatened to sideline serious inquiry over policy in this domain.

DiCaprio earned nominations for a Golden Globe and a BAFTA Award for the film. It broke the record for the most views (152 million hours) in a single week in Netflix history. DiCaprio next starred in Scorsese's crime drama Killers of the Flower Moon (2023) based on the book of the same name by David Grann, for which he was paid $30 million. Initially signed for the heroic part of FBI agent Thomas Bruce White Sr., DiCaprio insisted on playing the morally complex role of murderer Ernest Burkhart, leading to extensive script rewrites. Declaring it the best performance of DiCaprio's career, IndieWire's David Ehrlich wrote that "his nuanced and uncompromising turn as the cretinous Ernest Burkhart mines new wonders from the actor's long-standing lack of vanity". He received another Golden Globe nomination for his performance. DiCaprio next starred in Paul Thomas Anderson's film One Battle After Another (2025), alongside Sean Penn and Regina Hall. For his role as a washed-up ex-revolutionary, he received his seventh Academy Award acting nomination. In December 2025, DiCaprio confirmed he has been cast in an undisclosed role in Michael Mann's planned sequel to the 1995 film Heat. As of February 2026, DiCaprio began shooting What Happens at Night, helmed by Martin Scorsese, also starring Jennifer Lawrence and Mads Mikkelsen.

Injection of corticosteroids may or may not alleviate symptoms better than simulated (placebo) injections. There is no evidence that corticosteroid injection sustainably alters the natural history of the disease, which seems to be a gradual progression of neuropathy. Surgery to cut the transverse carpal ligament is the only known disease modifying treatment.

It is critical that the sample be processed before entering the mass spectrometer so that only a single chemical species enters at a given time. Generally, samples are combusted or pyrolyzed and the desired gas species (usually hydrogen (H2), nitrogen (N2), carbon dioxide (CO2), or sulfur dioxide (SO2)) is purified by means of traps, filters, catalysts and/or chromatography. The two most common types of IRMS instruments are continuous flow and dual inlet. In dual inlet IRMS, purified gas obtained from a sample is alternated rapidly with a standard gas (of known isotopic composition) by means of a system of valves, so that a number of comparison measurements are made of both gases. In continuous flow IRMS, sample preparation occurs immediately before introduction to the IRMS, and the purified gas produced from the sample is measured just once. The standard gas may be measured before and after the sample or after a series of sample measurements. While continuous-flow IRMS instruments can achieve higher sample throughput and are more convenient to use than dual inlet instruments, the yielded data is of approximately 10-fold lower precision.

Sources: en.wikipedia.org

Notes from published material

== Side Effects == There are no significant adverse side-effects of Prajmaline when taken alone and with a proper dosage. Patients who are taking other treatments for their symptoms (e.g. beta blockers and nifedipine) have developed minor transient conduction defects when given Prajmaline.

=== Impersonation attempts === Despite a seven-page document written by Twitter's content moderation team, on November 9, Twitter Blue launched with verification exclusively on iOS. Upon introducing paid verification, various individuals in sports Twitter were impersonated, such as sports writer Adam Schefter and basketball player LeBron James, with tweets announcing the supposed ousting of Las Vegas Raiders head coach Josh McDaniels or James' trade from the Los Angeles Lakers, respectively. As impersonation accounts began appearing for Nintendo and Tesla—the latter being owned by Musk—the official label returned. Other individuals and companies impersonated include former president Donald Trump, video game company Valve, and former New York City mayor Rudy Giuliani. One account impersonating the beverage corporation PepsiCo praised the superiority of Coca-Cola. Twitter paused signups for Twitter Blue on November 11; according to a Slack message obtained by Platformer reporter Zoë Schiffer, the company paused subscriptions to deal with impersonation attempts. Musk believed that impersonation would be resolved if Apple handed over the credit card information of Twitter Blue subscribers; then head of trust and safety Yoel Roth explained that Apple would not oblige to such a request. The Washington Post published a report on November 11 detailing how reporter Geoffrey Fowler was, with permission from United States senator Ed Markey, impersonating a U.S.

== In popular culture == The 1960 British war film Sink the Bismarck! discusses the strategic importance of the GIUK gap during World War II naval operations in the Atlantic theatre, and depicts the Battle of the Denmark Strait between British and German forces. It is based on the novel The Last Nine Days of the Bismarck by C. S. Forester. The GIUK line is mentioned in the film The Bedford Incident. In Tom Clancy's first novel, The Hunt for Red October, the line was used to detect Soviet submarines entering the North Atlantic in pursuit of the rogue Typhoon-class submarine Red October, whose officers were defecting to the United States with clandestine stealth technology. The event causes significant political and military tension between the United States and the Soviet Union. The film adaptation also references the gap, with National Security Advisor Jeffrey Pelt (played by Richard Jordan) saying to the Soviet ambassador "Your aircraft have dropped enough sonar buoys so that a man could walk from Greenland to Iceland to Scotland without getting his feet wet." In Clancy's second novel, Red Storm Rising, the line is featured more prominently after a war breaks out between NATO and the Warsaw Pact. The Soviet Union launches a surprise attack on the NATO airbase NAS Keflavik and invades Iceland. This causes the line to be destroyed, creating a gap in NATO's surveillance and allowing the Soviet Navy to enter the North Atlantic.

== Clinical trials == As of September 2024, traneurocin is in phase 3 clinical trials for COVID-19, phase 2 clinical trials for Alzheimer's disease, fragile X syndrome, and Rett syndrome, and phase 1 clinical trials for major depressive disorder. No development has been reported for treatment of other neurological disorders. Traneurocin was first developed, under the name cycloprolylglycine (CPG), in Russia in 1991 as a drug related structurally and pharmacologically to piracetam. Cycloprolylglycine is also related to and known to be the major metabolite of omberacetam (Noopept). Another drug, vineurocin (NA-704), is also being developed for treatment of Alzheimer's disease. This drug is described as a recombinant growth hormone with neuroprotective and neurogenic effects.

== Indications == DBNPA is used as a disinfectant, bactericide, algicide, slime remover, and mildew inhibitor in several industrial applications. It is frequently used to regulate the growth of bacteria, algae, and slime in oilfield water injection systems and circulating cooling water systems. DBNPA is used in the paper industry as a slime remover, bactericide, and algicide to keep machinery free of microorganisms and maintain product quality. Additionally, it is utilized as a preservative to prevent microbiological deterioration in paints, waxes, inks, detergents, surfactants, slurries, and resins. DBNPA also serves as a fungicide and algaecide in municipal water landscapes, guaranteeing water safety and clarity, and as a biocide in process water and air purifier systems in the machinery manufacturing sector. The concentration used when it is being used as a water treatment slime stripper is 30~50 mg/L. When it is being used for water treatment, as a bactericide, it is used at a concentration of 10~20 mg/L. In terms of analytical detection in industrial and environmental samples, high-performance liquid chromatography with UV detection, measuring absorption at 230 nm, detects DBNPA at extremely low concentrations (>0.1 mg/L) in water samples. Gas chromatography-mass spectrometry can also identify and quantify DBNPA and the associated degradation products, (detection limit is 0.05 mg/L) in environmental samples.

Sources: en.wikipedia.org

Frequently asked questions

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

What are the recommended storage conditions for AOD-9604?

Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.

What quality issues can arise with AOD-9604 products?

Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

Network